Contact
Please use this form to send email to PR contact of this press release:
Immunophotonics Announces 1st Patient Dosed in IP-IIO-622 Phase 1b/2a Clinical Trial in Advanced Solid Tumor Indications
TO:
Public Relations
Immunophotonics, Inc.